🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

RecruitingPhase 1Ages 18 Years - anyAllIncyte Corporation
NCT06179160 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * ≥18 years old. * Locally advanced or metastatic solid tumor with KRAS G12D mutation. * For Part 1a and Part 2 Combination Groups 1, 2, and 7: Disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, declined available therapies that are known to confer clinical benefit, or no standard available treatment to improve the disease outcome. * Cohort specific requirements aas defined in the protocol. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Exclusion Criteria: * Prior treatment with any KRAS G12D inhibitor * Known additional invasive malignancy within 1 year of the first dose of study drug * History of organ transplant, including allogeneic stem cell transplantation * Significant, uncontrolled medical condition * History or presence of an ECG abnormality * Inadequate organ function Other protocol-defined Inclusion/Exclusion Criteria may apply
💊

What it tests

  • INCB161734
  • Cetuximab
  • Retifanlimab
  • GEMNabP
  • mFOLFIRINOX
📍

Where

34 sites
Mayo Clinic Hospital
Phoenix, United States
Stanford University
Palo Alto, United States
UCLA Healthcare Hematology-Oncology
Santa Monica, United States
Sarah Cannon Research Institue At Healthone
Denver, United States
Florida Cancer Specialists
Sarasota, United States
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Baltimore, United States
Dana Farber Cancer Institute
Boston, United States
Hackensack University Medical Center
Hackensack, United States

…and 26 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy